Severe FECD increases risk of glaucoma and OHT

Article

Severe Fuchs endothelial corneal dystrophy (FECD) increases the risk of developing glaucoma and/or ocular hypertension (G/OHT).

Severe Fuchs endothelial corneal dystrophy (FECD) increases the risk of developing glaucoma and/or ocular hypertension (G/OHT).

Dr Mehul Nagarsheth et al., Wills Eye Institute/Jefferson Medical College, Philadelphia, Pennsylvania, USA, studied a subset of 1610 from the FECD Genetics Multi-Centre Study. Logistic regression models, adjusted for age, sex, central corneal thickness, IOP, presence of diabetes and time of day of the initial evaluation, were used.

Of the total eyes included in the study, 107 eyes had G/OHT and the prevalence of G/OHT in the control group was 6%. Eyes with a grade of four through to six were more likely to have concurrent G/OHT than eyes with no record of FECD.

Prevalence of G/OHT was lower in index cases with an FECD grade of one to three and family members with a grade of zero through to three. But it was higher in index cases and family members with a grade of four to six. The logistic regression models demonstrated no correlation between sex, diabetes, time of day of evaluation and central corneal thickness with prevalence of G/OHT.

The abstract can be found in the journal Archives of Ophthalmology.

Related Videos
ARVO 2024: Andrew D. Pucker, OD, PhD on measuring meibomian gland morphology with increased accuracy
 Allen Ho, MD, presented a paper on the 12 month results of a mutation agnostic optogenetic programme for patients with severe vision loss from retinitis pigmentosa
Noel Brennan, MScOptom, PhD, a clinical research fellow at Johnson and Johnson
ARVO 2024: President-elect SriniVas Sadda, MD, speaks with David Hutton of Ophthalmology Times
Elias Kahan, MD, a clinical research fellow and incoming PGY1 resident at NYU
Neda Gioia, OD, sat down to discuss a poster from this year's ARVO meeting held in Seattle, Washington
Eric Donnenfeld, MD, a corneal, cataract and refractive surgeon at Ophthalmic Consultants of Connecticut, discusses his ARVO presentation with Ophthalmology Times
John D Sheppard, MD, MSc, FACs, speaks with David Hutton of Ophthalmology Times
Paul Kayne, PhD, on assessing melanocortin receptors in the ocular space
Osamah Saeedi, MD, MS, at ARVO 2024
© 2024 MJH Life Sciences

All rights reserved.